OPIOID-INDUCED HYPERALGESIA IN PATIENTS WITH CHRONIC PAIN SYNDROME OF ONCOLOGICAL GENESIS

Abstract

The role of mechanisms of the onset of opioid-induced hyperalgesia in patients with chronic pain syndrome of oncological genesis is highlighted according to the review of results of the search for Russian and English articles in the scientific bases of PubMed, Scopus, Web of Science, eLibrary. The importance of genetic factors predetermining the development of opioid-induced hyperalgesia is shown. The key role of pharmacological preparations for relief of chronic pain in the conditions of opioid-induced hyperalgesia is presented.

Keywords

review / opioid-induced hyperalgesia / chronic pain syndrome / oncology / genetic polymorphism

References

[1] Kenan K., Mack K., Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000 - 2010. Open Med. 2012; 6(2): 41-7.

[2] Drewes A.M., Jensen R.D., Nielsen L.M., Droney J., Christrup L.L., Arendt-Nielsen L., Riley J., Dahan A. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br. J. Clin. Pharmacol. 2012; 75(1): 60-78. DOI: 10.1111/j.1365-2125.2012.04317.x

[3] Low Y., Clarke C.F., Huh B.K. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med. J. 2012; 53(5): 357-60.

[4] Yi P., Pryzbylkowski P. Opioid Induced Hyperalgesia. Pain Medicine. 2015; 16: 32-6. DOI: 10.1111/pme.12914

[5] Hooten W.M., Mantilla C.B., Sandroni P., Townsend C.O. Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering. Pain Med. 2010; 11: 1587-98. DOI: 10.1111/j.1526-4637.2010.00962.x

[6] Angst M.S., Clark J.D. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology. 2006; 104: 570-87. PMID:16508405.

[7] Lee M., Silverman S.M., Hansen H., Patel V.B., Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14(2): 145-61. PMID: 21412369.

[8] Bannister K., Lee Y.S., Goncalves L., Porreca F., Lai J., Dickenson A.H. Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord. Neuropharmacol. 2014; 85: 375-83. DOI: 10.1016/j.neuropharm.2014.06.005

[9] Fletcher D., Martinez V. Opioid-induced hyperalgesia in patients after surgery: A systematic review and a meta-analysis. Br. J. Anaesth. 2014; 112: 991-1004. DOI: 10.1093/bja/aeu137

[10] Chu L.F., Dairmont J., Zamora A.K., Young C.A., Angst M.S. The endogenous opioid system is not involved in modulation of opioid -induced hyperalgesia. J. Pain. 2011; 12: 108-15. DOI: 10.1016/j.jpain.2010.05.006

[11] Roeckel L.A., Le Coz G.M., Gaveriaux-Ruff C., Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience. 2016; 338:160-82. DOI: 10.1016/j.neuroscience.2016.06.029

[12] Shah M., Anwar M.A., Yesudhas D., Krishnan J., Choi S. A structural insight into the negative effects of opioids in analgesia by modulating the TLR4 signaling: an in silico approach. Sci. Rep. 2016; 6: 39271. DOI: 10.1038/srep39271

[13] Nicotra L., Loram L.C., Watkins L.R., Hutchinson M.R. Toll-like receptors in chronic pain. Exp. Neurol. 2012; 234: 316-29. DOI: 10.1016/j.expneurol.2011.09.038

[14] Jurga A.M., Rojewska E., Piotrowska A., Makuch W., Pilat D., Przewlocka B., Mika J. Blockade of toll-like receptors (TLR2, TLR4) attenuates pain and potentiates buprenorphine analgesia in a rat neuropathic pain model. Neural. Plast. 2016; 2016: 5238730. DOI: 10.1155/2016/5238730

[15] Shi X.Q., Zekki H., Zhang J. The role of TLR2 in nerve injury-induced neuropathic pain is essentially mediated through macrophages in peripheral inflammatory response. Glia. 2011; 59(2): 231-41. DOI: 10.1002/glia.21093

[16] Kim D., You B., Lim H., Lee S.J. Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury. Mol. Pain. 2011; 7: 74. DOI: 10.1186/1744-8069-7-74

[17] Graeber M.B., Streit W.J. Microglia: biology and pathology. Acta Neuropathol. 2010; 119(1): 89-105. DOI: 10.1007/s00401-009-0622-0

[18] Hutchinson M.R., Shavit Y., Grace P.M., Rice K.C., Maier S.F., Watkins L.R. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol. Rev. 2011; 63(3): 772-810. DOI: 10.1124/pr.110.004135

[19] Doyle H.H., Murphy A.Z. Sex differences in innate immunity and its impact on opioid pharmacology. J. Neurosci. Res. 2017; 95(1-2): 487-99. DOI: 10.1002/jnr.23852

[20] Ben Achour S., Pascual O. Glia: the many ways to modulate synaptic plasticity. Neurochem. Int. 2010; 57(4): 440-5. DOI: 10.1016/j.neuint.2010.02.013

[21] Eidson L.N., Murphy A.Z. Blockade of toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine. J. Neurosci. 2013; 33(40): 15952-63. DOI: 10.1523/jneurosci.1609-13.2013

[22] Akbari E. The role of cyclo-oxygenase inhibitors in attenuating opioid-induced tolerance, hyperalgesia, and dependence. Med. Hypotheses. 2012; 78(1): 102-6. doi: 10.1016/j.mehy.2011.10.003

[23] Bravo-Hernández M., Cervantes-Durán C., Pineda-Farias J.B., Barragán-Iglesias P., López-Sánchez P., Granados-Soto V. Role of peripheral and spinal 5-HT(3) receptors in development and maintenance of formalin-induced long-term secondary allodynia and hyperalgesia. Pharmacol. Biochem. Behav. 2012; 101: 246-57. DOI: 10.1016/j.pbb.2012.01.013

[24] Lenz H., Raeder J., Draegni T., Heyerdahl F., Schmelz M., Stubhaug A. Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. Pain. 2011; 152(6): 1289-97. DOI: 10.1016/j.pain.2011.02.007

[25] Richebé P., Pouquet O., Jelacic S., Mehta S., Calderon J., Picard W., Rivat C., Cahana A., Janvier G. Target-controlled dosing of remifentanil during cardiac surgery reduces postoperative hyperalgesia. J. Cardiothor. Vasc. Anesthesia. 2011; 25 (6): 917-25. DOI: 10.1053/j.jvca.2011.03.185

[26] Johnson J.L., Rolan P.E., Johnson M.E., Bobrovskaya L., Williams D.B., Johnson K., Tuke J., Hutchinson M.R. Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation. Transl. Psychiatry. 2014; 4: e482. DOI: 10.1038/tp.2014.121

[27] Johnson J.L., Hutchinson M.R., Williams D.B., Rolan P. Medication-overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia. 2013; 33(1): 52-64. DOI: 10.1177/0333102412467512

[28] Carullo V., Fitz-James I., Delphin E. Opioid-Induced hyperalgesia: a diagnostic dilemma. Journal of Pain & Palliative Care Pharmacotherapy. 2015; 29 (4): 378-84. DOI:10.3109/15360288. 2015.1082006

[29] Von Korff M.R. Long-term use of opioids for complex chronic pain. Best Pract. Res. Clin. Rheumatol. 2013; 27(5): 663-72. DOI: 10.1016/j.berh.2013.09.011

[30] Gris P., Gauthier J., Cheng P., Gibson D.G., Gris D. et al. A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Molecular Pain. 2010; 6: 33. http://www.molecularpain.com/content/6/1/33

[31] Corder G., Tawfik V.L., Wang D., Sypek E.I., Low S.A. et al. Loss of mu opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia. Nat. Med. 2017; 23: 164-73. DOI: 10.1038/nm.4262

[32] Convertino M., Samoshkin A., Gauthier J., Gold M.S., Maixner W. et al. Mu-opioid receptor 6-transmembrane isoform: a potential therapeutic target for new efective opioids. Prog. Neuropsychopharmacol. Biol. Psychiat. 2015; 62: 61-7. DOI: 10.1016/j.pnpbp.2014.11.009

[33] Боброва О.П., Шнайдер Н.А., Зырянов С.К., Модестов А.А. Ассоциация полиморфизма гена опиоидных рецепторов OPRM1 с фенотипическим разнообразием хронического болевого синдрома онкологического генеза. Медицинская генетика. 2017; 16(6): 3-8.

[34] Roeckel L.-A., Utard V., Reiss D., Mouheiche J., Maurin H., Robé A., Audouard E., Wood J.N., Goumon Y., Simonin F., Gaveriaux-Ruff C. Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide. Sci. Rep. 2017; 7: 10406. DOI: 10.1038/s41598-017-11120-4

[35] Gessi S., Borea P.A., Bencivenni S., Fazzi D., Varani K., Merighi S. The activation of mu-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia. FEBS Lett. 2016; 590(17): 2813-26. DOI: 10.1002/1873-3468.12313

[36] Wise H. The roles played by highly truncated splice variants of G protein-coupled receptors. J. Mol. Signal. 2012; 7: 1-13.

[37] Lagerström M.C., Rogoz K., Abrahamsen B., Persson E., Reinius B. et al. VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch. Neuron. 2010; 68: 529-42. DOI: 10.1016/j.neuron.2010.09.016

[38] Fernández-de-las-Peñas C., Fernández-Lao C., Cantarero-Villanueva I., Ambite-Quesada S., Rivas-Martínez I. et al. Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors. Breast Cancer Res. Treat. 2012; 133(2): 405-12. DOI: 10.1007/s10549-011-1757-y

[39] Kotlovskiy M.Yu., Pokrovskiy A.A., Kotlovskaya O.S., Osedko A.V., Osedko O.Ya., Titova N.M., Titov V.N., Kotlovskiy Yu.V., Trifonova O.Yu., Dygay A.M. Gen SLCO1B1 v aspekte farmakogenetiki. Sibirskoe meditsinskoe obozrenie. 2015; (1): 5-15. (in Russian) / Котловский М.Ю., Покровский А.А., Котловская О.С., Оседко А.В., Оседко О.Я., Титова Н.М., Титов В.Н., Котловский Ю.В., Трифонова О.Ю., Дыгай А.М. Ген SLCO1B1 в аспекте фармакогенетики. Сибирское медицинское обозрение. 2015; 1: 5-15.

[40] Berta T., Liu Y.-C., Xu Z.-Z., Ji R.-R. Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allody-nia via astrocytic IL-1β and ERK signaling in the spinal cord of mice. Neuroscience. 2013; 247: 376-85. DOI: 10.1016/j.neuroscience.2013.05.018

[41] Chen Y., Yang C., Wang Z.J. Ca2+/calmodulin-dependent protein kinase IIα is required for the initiation and maintenance of opioid-induced hyperalgesia. J. Neurosci. 2010; 30 (1): 38-46. DOI: 10.1523/jneurosci.4346-09.2010

[42] Liang D.-Y., Zheng M., Sun Y., Sahbaie P., Low S.A. et al. The Netrin-1 receptor DCC is a regulator of maladaptive responses to chro-nic morphine administration. BMC Genomics. 2014; 15: 345. DOI: 10.1186/1471-2164-15-345

[43] Oladosu F.A., Conrad M.S., O’Buckley S.C., Rashid N.U. et al. Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia. PLoS One. 2015; 10(8): e0135711. DOI: 10.1371/journal.pone.0135711

[44] Gaveriaux-Ruff C. Opiate-induced analgesia: contributions from mu, delta and kappa opioid receptors mouse mutants. Curr. Pharm. Des. 2013; 19: 7373-81. PMID: 23448470.

[45] Ellis A., Grace P.M., Wieseler J., Favret J., Springer K. et al. Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury. Brain. Behav. Immun. 2016; 58: 348-56. DOI: 10.1016/j.bbi.2016.08.004

[46] Arout C.A., Caldwell M., Rossi G., Kest B. Spinal and supraspinal N-methyl-D-aspartate and melanocortin-1 receptors contribute to a qualitative sex difference in morphine-induced hyperalgesia. Physiol. Behav. 2015; 147; 364-72. DOI: 10.1016/j.physbeh.2015.05.006

[47] Forero M., Chan P.S., Restrepo-Garces C.E. Successful reversal of hyperalgesia/myoclonus complex with lowdose ketamine infusion. Pain Pract. 2012; 12(2): 154-8. DOI: 10.1111/j.1533-2500.2011.00475.x

[48] Salpeter S.R., Buckley J.S., Bruera E. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J. Palliat. Med. 2013; 16(6): 616-22. DOI: 10.1089/jpm.2012.0612

[49] Aguado D., Abreu M., Benito J., Garcia-Fernandez J., Gómez de Segura I.A. Effects of naloxone on opoid-induced hyperalgesia and tole-rance to remifentanil under sevoflurane anesthesia in rats. Anesthesio-logy. 2013; 118(5): 1160-9. DOI: 10.1097/ALN.0b013e3182887526

[50] Berna C., Kulich R.J., Rathmell J.P. Tapering long-term opioid therapy in chronic noncancer pain: Evidence and recommendations for everyday practice. Mayo. Clin. Proc. 2015; 90: 828-42. DOI: 10.1016/j.mayocp.2015.04.003

[51] Mercadante S., Ferrera P., Arcuri E., Casuccio A. Opioid-induced hyperalgesia after rapid titration with intravenous morphine: switching and re-titration to intravenous methadone. Ann. Palliat. Med. 2012; 1(1): 10-3. DOI: 10.3978/j.issn.2224-5820.2012.01.02

[52] Monterubbianesi M.C., Capuccini J., Ferioli I., Tassinari D., Sarti D., Raffaeli W. High opioid dosage rapid detoxification of cancer patient in palliative care with the Raffaeli model. J. Opioid Manag. 2012; 8(5): 292-8. DOI: 10.5055/jom.2012.0129

[53] Gomes T., Mamdani M.M., Dhalla I.A., Paterson J.M., Juurlink D.N. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch. Intern. Med. 2011; 171(7): 686-91. DOI: 10.1001/archinternmed.2011.117

RIGHTS & PERMISSIONS

Eco-Vector